Cost-effectiveness of rule-based immunoprophylaxis against respiratory syncytial virus infections in preterm infants.

ABSTRACT: The objective of the paper is to assess the cost-effectiveness of targeted respiratory syncytial virus (RSV) prophylaxis based on a validated prediction rule with 1-year time horizon in moderately preterm infants compared to no prophylaxis. Data on health care consumption were derived from a randomised clinical trial on wheeze reduction following RSV prophylaxis and a large birth cohort study on risk prediction of RSV hospitalisation. We calculated the incremental cost-effectiveness ratio (ICER) of targeted RSV prophylaxis vs. no prophylaxis per quality-adjusted life year (QALYs) using a societal perspective, including medical and parental costs and effects. Costs and health outcomes were modelled in a decision tree analysis with sensitivity analyses. Targeted RSV prophylaxis in infants wi

SUBMITTER: Blanken MO 

PROVIDER: S-EPMC5748402 | biostudies-literature | 2018 Jan

REPOSITORIES: biostudies-literature